微創醫療(00853.HK):MicroPort CardioFlow Medtech Corporation引入戰投1.3億美元
格隆匯4月16日丨微創醫療(00853.HK)公告,於2020年4月15日,目標公司MicroPort CardioFlow Medtech Corporation與投資者訂立該協議,據此,投資者同意以總代價約1.3億美元投資目標公司合共1167萬股股份。
目標公司為一間根據開曼羣島法律正式註冊成立並有效存續的獲豁免有限責任公司。其主要透過其附屬公司從事研究、開發及商業化治療瓣膜性心臟病的醫療器械。該代價系與投資者公平磋商並參考目標公司緊接於該協議完成前的估值11億美元而釐定。
該協議完成後,將向目標公司引入額外的外在投資者,預期將為目標公司的研發、製造及市場擴展以及增強其市場競爭力帶來更多的市場資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.